小干扰RNA
结直肠癌
免疫系统
转移
抗药性
癌症研究
长非编码RNA
癌症
医学
生物
免疫学
核糖核酸
基因
内科学
遗传学
作者
Harikumar Pallathadka,Chou‐Yi Hsu,Raed Obaid Saleh,S. Renuka Jyothi,Ashwani Kumar,Alexey Yumashev,Aashna Sinha,Ahmed Hussein Zwamel,Mohammed Abed Jawad,Salim B. Alsaadi
标识
DOI:10.1016/j.intimp.2024.112730
摘要
Colorectal cancer (CRC) involves various genetic alterations, with liver metastasis posing a significant clinical challenge. Furthermore, CRC cells mostly show an increase in resistance to traditional treatments like chemotherapy. It is essential to investigate more advanced and effective therapies to prevent medication resistance and metastases and extend patient life. As a result, it is anticipated that small interfering RNAs (siRNAs) would be exceptional instruments that can control gene expression by RNA interference (RNAi). In eukaryotes, RNAi is a biological mechanism that destroys specific messenger RNA (mRNA) molecules, thereby inhibiting gene expression. In the management of CRC, this method of treatment represents a potential therapeutic agent. However, it is important to acknowledge that siRNA therapies have significant issues, such as low serum stability and nonspecific absorption into biological systems. Delivery mechanisms are thus being created to address these issues. In the current work, we address the potential benefits of siRNA therapy and outline the difficulties in treating CRCby focusing on the primary signaling pathways linked to metastasis as well as genes implicated in the multi-drug resistance (MDR) process.
科研通智能强力驱动
Strongly Powered by AbleSci AI